The Clinical Observations of the Treatment of Non-small Cell Lung Cancer with CT-guided Percutaneous Embedding of ~(125)I Particles in Combination with Chemotherapy / 昆明医科大学学报

ABSTRACT

Objective To observe the clinical effectiveness and adverse side effects of percutaneous embedding of ~(125)I particles in combination with chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods Twenty-one patients with advanced NSCLC(IIIa-IIIb phase) received percutaneous embedding of ~(125)I particles in combination with concurrent chemotherapy.The chemotherapy was conducted in accordance with TP regime(paclitaxel at 135 mg/m~2 and cisplatin at 30 mg/m~2 were administered on day 1 and on day 2 to 4,respectively with 28 days as a cycle).12～75 ~(125)I particles were embedded with CT-guided percutaneous puncture one week after chemotherapy.The radioactivity quantum was 22～33 MBq per particle.The overall radioactivity quantum of embedded particles was 264-1650 MBq with one or more puncture points.Chemotherapy was then continued for two cycles.Results All the 21 patients completed the therapy,among whom,23.80% got complete response(CR),66.67% got partial response(PR) and 9.53% had stable or progressive disease(NC+PD) with an overall response(CR+PR) of 90.48%.The complications included hemopneumothorax(33.34%),hemorrhage(4.77%),particle migration(4.77%).The incidence rates of radiation esophagitis and radiation pneumonia with grade 1～2 were 4.77%(1/21) and 4.77%(1/21) respectively.No radiation esophagitis or radiation pneumonia with grade 3～4 was found.The incidence rate of grade 3～4 acute myelosuppression comprises 52.38% leucocytopenia,9.53% thrombocytopenia,28.58% decrease of hemoglobin,grade III-IV nausea and 42.86%vomiting,38.10% grade III-IV alopecia.The 1-year survival rate was 80.96%.The 12-month local control rate was 85.72%. Conclusion The results have shown that CT-guided percutaneous embedding of ~(125)I particles in combination with chemotherapy was effective and well-tolerable with few complications and good compliance.